Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
#5PRI RANKED
Most Cited Paper
in Immune Cell Function and Interaction
18 Months Post-Publication
Class of 2026
“Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/immune-cell-function-and-interaction/2026/
Topics
JAK inhibition · itacitinib · PD-1/PD-L1 blockade · type-I interferon · persistent inflammation · Immunosuppression · Non-small cell lung cancer · phase 2 clinical trial · CD8 T cell plasticity · T cell exhaustion · effector memory-like T cells · T cell clonotypes · terminal differentiation · combination immunotherapy · Antitumor efficacy · mouse tumor model · progressive disease · Immunotherapy resistance · cytokine-driven immune dysfunction · T cell differentiation dynamics
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Immune Cell Function and Interaction Papers, Class of 2026. https://pri.pepkio.com/top-papers/immune-cell-function-and-interaction/2026. Accessed 2026-07-15. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459